Monoamine oxidase inhibition and neuroprotection by N1-propargylphenelzine
β Scribed by B. Duff Sloley; Liana J. Urichuk; Ling Lei; Ronald T. Coutts; Glen B. Baker; Jaqueline J. Shan; Peter K.T. Pang
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 120 KB
- Volume
- 53
- Category
- Article
- ISSN
- 0272-4391
- DOI
- 10.1002/ddr.1164
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Recent clinical studies suggest that selegiline (1.-deprenyl) is useful in retarding the progress of Parkinson's disease. an effect that may bc related to its inhibition of monoamine oxidase type B (MAO-B). Selegilinc is also reported to prevent the toxic effects of the norddrenergic neurotoxin, h~-
Our preliminary observations on the relationship of sleep and lumbar CSF acid monoamine metabolite levels suggested a greater decrease in lumbar CSF HVA as compared to 5HIAA following clinical doses of phenelzine in the presence of virtually total REM suppression. This report on nine psychiatric pat